The use of next-generation sequencing (NGS) technologies to detect B-cell receptor (BCR) or T-cell receptor (TCR) clonotypes ...
Long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment Preclinical efficacy in ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
Chinese cell therapy company NewCure Biotech has raised more than 200 million yuan ($28 million) in a series B round to ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic ...
Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results